Funds and ETFs XOMA Corporation

Equities

XOMA

US98419J2069

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-01 pm EDT 5-day change 1st Jan Change
25.82 USD +1.89% Intraday chart for XOMA Corporation +0.70% +39.57%

ETFs positioned on XOMA Corporation

Name Weight AuM 1st Jan change Investor Rating
0.22% 27 M€ -5.94% -
0.00% 34 M€ +1.32% -
XOMA Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
25.82 USD
Average target price
57 USD
Spread / Average Target
+120.76%
Consensus
  1. Stock Market
  2. Equities
  3. XOMA Stock
  4. Funds and ETFs XOMA Corporation